BioCentury

8:00 AM GMT, Feb 20, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Externalizing neurology

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high attrition rates.

The company says its neuroscience investment will continue at current levels despite large headcount reductions, and adopting a new model focused on externalization will give CNS-focused biotechs even more opportunity to collaborate with the pharma.

AstraZeneca this month announced a restructuring that includes a 7,300-person headcount reduction. About 2,200 of this is coming from R&D.

The transition of the neuroscience innovative medicines unit (iMED) to a virtual R&D model is a major component of the R&D revamp. The move is consistent with changes that began in 2010, when

Read the full 1245 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.